Bleomycin for Injection, USP – prescribing information (WARNINGS: pulmonary toxicity) (2022)

Government Record · Hospira, Inc. (label); U.S. Food and Drug Administration (approval) · August 2022

Hospira et al., 2022-08: The bleomycin label states pulmonary toxicity in 10% of treated patients and progression to pulmonary fibrosis and death in about 1%, with higher risk above 400 units total dose and in the elderly.

Pulmonary toxicities occur in 10% of treated patients. In approximately 1%, the nonspecific pneumonitis induced by bleomycin progresses to pulmonary fibrosis and death.

PDF p.4 (WARNINGS)

Hospira et al., 2022-08: The bleomycin label states pulmonary toxicity in 10% of treated patients and progression to pulmonary fibrosis and death in about 1%, with higher risk above 400 units total dose and in the elderly. Regulatory text: no funder/COI; maker Hospira (Pfizer). The label also warns that toxicity is unpredictable and has occurred in young patients at low doses, and recommends chest radiographs every 1-2 weeks. The 'up to 10%' claim matches the label exactly; the mortality figure the claim asks for is the label's ~1%. Study type: regulatory record.